LV11524B - Use of benzydamine in the treatment of pathological conditions caused by tnf - Google Patents

Use of benzydamine in the treatment of pathological conditions caused by tnf Download PDF

Info

Publication number
LV11524B
LV11524B LVP-96-46A LV960046A LV11524B LV 11524 B LV11524 B LV 11524B LV 960046 A LV960046 A LV 960046A LV 11524 B LV11524 B LV 11524B
Authority
LV
Latvia
Prior art keywords
tnf
benzidamine
acid addition
physiologically acceptable
acceptable acid
Prior art date
Application number
LVP-96-46A
Other languages
English (en)
Latvian (lv)
Other versions
LV11524A (lv
Inventor
Cioli Valerio
Original Assignee
Angelini Ricerche Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angelini Ricerche Spa filed Critical Angelini Ricerche Spa
Publication of LV11524A publication Critical patent/LV11524A/xx
Publication of LV11524B publication Critical patent/LV11524B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LVP-96-46A 1993-07-27 1996-02-15 Use of benzydamine in the treatment of pathological conditions caused by tnf LV11524B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT93MI001673A IT1276040B1 (it) 1993-07-27 1993-07-27 Uso della benzidamina nel trattamento di stati patologici causati dal tnf
PCT/EP1994/002343 WO1995003799A1 (en) 1993-07-27 1994-07-14 Use of benzydamine in the treatment of pathological conditions caused by tnf

Publications (2)

Publication Number Publication Date
LV11524A LV11524A (lv) 1996-10-20
LV11524B true LV11524B (en) 1996-12-20

Family

ID=11366694

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-96-46A LV11524B (en) 1993-07-27 1996-02-15 Use of benzydamine in the treatment of pathological conditions caused by tnf

Country Status (25)

Country Link
US (1) US6300358B1 (pt)
EP (1) EP0711163B1 (pt)
JP (1) JP3587851B2 (pt)
CN (1) CN1085528C (pt)
AT (1) ATE207353T1 (pt)
AU (1) AU692458B2 (pt)
BG (1) BG62841B1 (pt)
CA (1) CA2167926C (pt)
CZ (1) CZ285864B6 (pt)
DE (1) DE69428797T2 (pt)
DK (1) DK0711163T3 (pt)
ES (1) ES2163450T3 (pt)
HU (1) HU226805B1 (pt)
IT (1) IT1276040B1 (pt)
LV (1) LV11524B (pt)
NO (1) NO308195B1 (pt)
NZ (1) NZ269563A (pt)
PL (1) PL312741A1 (pt)
PT (1) PT711163E (pt)
RO (1) RO117149B1 (pt)
RU (1) RU2160102C2 (pt)
SI (1) SI0711163T1 (pt)
SK (1) SK281895B6 (pt)
WO (1) WO1995003799A1 (pt)
ZA (1) ZA945431B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101199515B (zh) * 2007-12-21 2010-12-08 重庆市莱美药物技术有限公司 盐酸苄达明洗剂及其制备方法
MY160002A (en) * 2009-02-10 2017-02-15 Celgene Corp Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
SG10201403088XA (en) * 2009-07-08 2014-10-30 Acraf USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES
MD4291C1 (ro) * 2013-12-27 2015-02-28 Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова Preparat medicamentos pentru tratamentul otitelor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054833A (pt) * 1963-08-09
US4980160A (en) * 1986-10-16 1990-12-25 Biogen, Inc. Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases
US5563143A (en) * 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release

Also Published As

Publication number Publication date
CN1085528C (zh) 2002-05-29
DE69428797T2 (de) 2002-04-18
NZ269563A (en) 2001-03-30
CN1130872A (zh) 1996-09-11
RO117149B1 (ro) 2001-11-30
DK0711163T3 (da) 2001-11-26
NO960347L (no) 1996-03-07
HU226805B1 (en) 2009-10-28
AU692458B2 (en) 1998-06-11
CZ285864B6 (cs) 1999-11-17
HUT73500A (en) 1996-08-28
NO308195B1 (no) 2000-08-14
WO1995003799A1 (en) 1995-02-09
NO960347D0 (no) 1996-01-26
EP0711163B1 (en) 2001-10-24
ATE207353T1 (de) 2001-11-15
SI0711163T1 (en) 2001-12-31
ZA945431B (en) 1995-02-28
DE69428797D1 (de) 2001-11-29
ITMI931673A0 (it) 1993-07-27
AU7386194A (en) 1995-02-28
CA2167926A1 (en) 1995-02-09
US6300358B1 (en) 2001-10-09
JPH09500385A (ja) 1997-01-14
LV11524A (lv) 1996-10-20
BG100385A (bg) 1996-09-30
CA2167926C (en) 2004-12-21
PL312741A1 (en) 1996-05-13
PT711163E (pt) 2002-04-29
RU2160102C2 (ru) 2000-12-10
ES2163450T3 (es) 2002-02-01
CZ25596A3 (en) 1996-07-17
EP0711163A1 (en) 1996-05-15
IT1276040B1 (it) 1997-10-24
JP3587851B2 (ja) 2004-11-10
ITMI931673A1 (it) 1995-01-27
SK10596A3 (en) 1997-03-05
BG62841B1 (bg) 2000-09-29
SK281895B6 (sk) 2001-09-11

Similar Documents

Publication Publication Date Title
EP1414428B1 (en) Histone deacetylase enzyme-inhibiting derivatives of hydroxamic acid as new cytokine synthesis-inhibiting anti-inflammatory drugs
US4794114A (en) Inhibition of interleukin-1 production by monocytes and/or macrophages
DE69233643T2 (de) Verwendung von Antizytokin-enthaltenden pharmazeutischen Zusammensetzungen zur Therapie von multipler Sklerose
US5593665A (en) Pharmaceutical compositions
RU95107881A (ru) Фармацевтическая композиция для лечения аллергических заболеваний, способ антигистаминного лечения, применение композиции для получения лекарственного препарата
US5767087A (en) Pharmaceutical preparation for the therapy of immune deficiency conditions
JPH09508115A (ja) 金属タンパク質分解酵素阻害剤としてのヒドロキサム酸誘導体
US6071919A (en) Zwitterionic compositions and methods as biological response modifiers
EP0711163B1 (en) Use of benzydamine in the treatment of pathological conditions caused by tnf
US5547971A (en) Use of leflunomide for inhibiting interleukin 8
WO1991002529A2 (en) Product and method for killing abnormal vertebrate cells
US5665371A (en) Medicines which contain derivatives of proline or hydroxyproline
EP1419777A1 (en) Use of glycyrrhizin and its derivatives as MCP-1 production inhibitors
US5369119A (en) Use of imexon as an immune suppressive and pharmaceutical compositions containing imexon
EP0377823A2 (en) Use of TNF for the preparation of a medicament for the treatment of psoriasis
KR20080014017A (ko) (5ｚ)-5-(6-퀴녹살리닐메틸리덴)-2-[(2,6-디클로로페닐)아미노]-1,3-티아졸-4(5ｈ)-온
KR100508623B1 (ko) 마크롤라이드 화합물의 신규한 용도
JPH06503084A (ja) 芳香族アルデヒドおよびその誘導体、ならびに皮膚病および関節炎の治療に有用なそれらの医薬学的組成物
EP1421942A1 (en) Use of glycyrrhizin and its derivatives as RANTES inducers
AU619027B2 (en) Method for suppressing immune responses by administering imexon
EP0423618A1 (en) Inosine/guanosine derivatives as immunosuppressive agents
JPS61129124A (ja) 抗腫瘍剤
US5814611A (en) Pharmaceutical for the therapy of immune deficiency conditions
JPH1160483A (ja) Ｔｎｆ産生阻害剤
DE102005013622A1 (de) Synthese substituierter Thieno[2,3-d:4,5-d']dipyrimidin-2,4(1H,3H)-dione und -4(3H)-one als TNFα-Freisetzungshemmer